Skip to main content
. 2022 May 21;112(3):699–710. doi: 10.1002/cpt.2633

Figure 7.

Figure 7

Relative CL of drugs in healthy (blue), and cancer‐D (red) to new cancer‐ALN (a) or new cancer‐ALC (b) populations, and new cancer‐ALN (white) to new cancer‐ALC (b) populations. Healthy: default abundances of enzymes and transporters (Simcyp) with a healthy population. Cancer‐D: default abundances of enzymes and transporters (Simcyp) with a cancer population. New Cancer‐ALN: abundance of enzymes and transporters measured in this study for histologically normal tissue with a cancer population. New Cancer‐ALC: abundances of enzymes and transporters measured in this study for cancer tissue with a cancer population. The green rectangle shows the drugs with less than 2‐fold change in drug clearance (CL) than that obtained using the new cancer‐ALC model, the amber shows 2 to 5‐fold higher CL than that obtained using the new cancer‐ALC model, and the red shows more than 5‐fold higher CL than that obtained using the new cancer‐ALC model.